||1R01CA160890-01A1 Interpret this number
||University Of California Los Angeles
||Adrenergic Regulation of Tumor Inflammation and Metastatic Dissemination
DESCRIPTION (provided by applicant): The metastatic microenvironment is receiving increasing attention as a target for new breast cancer therapies. The sympathetic nervous system (SNS) is a component of this microenvironment, and our recent studies indicated that SNS activity may support metastasis through beta-adrenergic pathways that recruit macrophages and induce a switch to pro-metastatic gene expression. Development of novel adjunctive therapeutic strategies that target neural regulation of metastasis requires characterization of the relationships between the SNS, the immune system and tumor cells. To address this need, the proposed studies utilize multimodal in vivo imaging techniques to address the following specific aims:
1. characterize SNS regulation of tumor cells in breast cancer metastasis,
2. characterize SNS regulation of tumor-associated macrophages in breast cancer metastasis,
3. characterize SNS regulation of the tumor microenvironment in breast cancer metastasis.
These studies will define interactions between SNS nerve fibers, tumor cells and macrophages in the context of the tumor microenvironment and elucidate their collective effects on metastasis. Given recent clinical studies that suggest beta-blockade reduces breast cancer recurrence, the proposed studies are urgently needed to establish a mechanistic foundation for rapid translation of existing compounds (beta-blockers) and development of novel biomarkers of early cancer progression and new anti-metastatic strategies that target SNS regulation of the tumor microenvironment.
PUBLIC HEALTH RELEVANCE: Metastasis is the major cause of morbidity and mortality in breast cancer. The studies described here evaluate the translational opportunity of targeting the sympathetic nervous system as a key regulator of pro-metastatic tumor-associated macrophages and tumor cell dissemination. These studies provide mechanistic foundation for development of novel anti-metastatic therapies that target neural regulation of the tumor microenvironment.
PEGylation of interferon ?2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.
Kaminskas LM, Ascher DB, McLeod VM, Herold MJ, Le CP, Sloan EK, Porter CJ
J Control Release, 2013 Jun 10;168(2), p. 200-8.
2013 Mar 15.